Paperonium

← Back to the plain-language case

Abstract states no severe treatment-related adverse events; the paper's Table 3 and Results report two

BMC Med (2026) · doi:10.1186/s12916-026-04695-1 · PMC13032705

Summary

The Abstract's only safety result reads "No dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TRAEs) were reported". The Discussion repeats this as "No DLTs or serious TRAEs were observed". The paper's own Results text and Table 3 report grade ≥ 3 TRAEs in 2 of the 87 Part III patients (2.3%; exact 95% CI 0.3% to 8.1%): a grade 5 (fatal) dyspnea in the head and neck squamous cell carcinoma (HNSCC) cohort and a grade 3 anemia in the sarcoma cohort. Table 3 also counts 2 patients under "TRSAE", which its footnote defines as "treatment-related severe adverse events". Under the CTCAE v5.0 grading the paper uses, grade 3 means severe, so the zero in the summary statements contradicts the paper's own count. The paper is also inconsistent about the fatal event: it calls the grade 5 dyspnea a TRAE, yet says that none of the 6 deaths "was attributed to T3011". In a first-in-human trial, a possible treatment-related death is a safety signal readers need to see in the Abstract.

What the paper reports

All quotations were checked verbatim against the PMC-archived text with src/show.py. The passages from the Abstract, Results, Table 3 and Discussion were also checked against the publisher's version of record.

Abstract, Results (the last sentence of the paragraph, which reports the Part III results):

No dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TRAEs) were reported.

Abstract, Conclusions:

T3011 shows a favorable safety profile, immune-modulating effects, and preliminary efficacy in patients with advanced solid tumors.

Results > Safety (Part III, N = 87):

Grade ≥ 3 TRAEs occurred in 2 (2.3%) patients, one case occurred in an HNSCC patient (grade 5, dyspnea), and another in a sarcoma patient (grade 3, anemia). Adverse events led to T3011 discontinuation in 4 patients (4.6%) and death in 6 patients (6.9%). The causes of death included pulmonary infection (n = 1), dyspnea (n = 1), respiratory failure (n = 1), cerebral infarction (n = 1), and death of unknown cause (n = 2). However, none of these was attributed to T3011.

Overall, the NCI CTCAE grades for these common TRAEs with an incidence exceeding 5% were predominantly grade 1 or 2, with only one grade 3 event (anemia) occurring in the sarcoma cohort.

Table 3, "Safety summary" (columns HNSCC N = 28 / BC N = 12 / Sarcoma N = 44 / Melanoma N = 1 / Others N = 2 / Total N = 87):

TRSAE | 1 (3.6) | 0 | 1 (2.3) | 0 | 0 | 2 (2.3)

≥ Grade 3 TRAE | 1 (3.6) | 0 | 1 (2.3) | 0 | 0 | 2 (2.3)

Table 3 footnote:

TRSAE treatment-related severe adverse events

Discussion, first paragraph:

No DLTs or serious TRAEs were observed, consistent with previously reported general tolerable safety profiles of intratumoral oncolytic viral therapies

Conclusions:

demonstrating a favorable safety profile, immune-modulating effects, and preliminary efficacy, particularly in patients with recurrent or metastatic HNSCC

Methods (grading and the DLT definition):

Adverse events were graded according to the NCI-CTCAE version 5.0.

AEs were coded using the MedDRA version 26.0 or higher and categorized by system organ class and preferred terms, severity (CTCAE v5.0 grades 1–5), and relationship to the study drug.

The DLT evaluation period was defined as 28 days from the initial administration of T3011.

Grade 5 toxicities (death) and other toxicity-driven premature treatment discontinuations adjudicated by investigators/sponsors were also considered DLTs.

Results > Patients and treatments > Part I and II:

Based on the safety data from both Part I and Part II, no DLT events were reported. No SAE, TRAE leading to discontinuation of T3011 or death was observed.

What the paper's own numbers show

Method. I transcribed all ten rows of Table 3 and all seven rows of Table 4. For each row I summed the five cohort counts, compared the sum with the printed total, and recomputed every printed percentage from the cohort sizes (28, 12, 44, 1, 2; total 87). I then checked the percentages in the Results > Safety text against the same denominators. Exact (Clopper-Pearson) 95% intervals were computed for the grade ≥ 3 TRAE proportions. Every number below is printed by recompute.py.txt.

The tables are arithmetically consistent: every row sum and every percentage in Tables 3 and 4 matches the printed value. (Two cosmetic points in the PMC-archived Table 3: the row label reads "≥ Grade TEAE", without the 3, where the Results give the matching 17.2% for "≥ Grade 3 AEs"; and the sarcoma cell of "TEAE leading to death" is printed as "1" with no percentage, which would be 2.3%.) The problem is not arithmetic. The summary statements give a count of zero where the paper's own table and text give two.

Quantity Location Reported Recomputed from the paper's own numbers
Severe TRAEs, Part III Abstract, Results none ("No … severe treatment-related adverse events (TRAEs) were reported") 2 of 87 (Table 3 and Results text)
Serious TRAEs Discussion none ("No DLTs or serious TRAEs were observed") 2 of 87 under TRSAE in Table 3; one of the two is graded fatal
≥ Grade 3 TRAE, total Table 3; Results > Safety 2 (2.3%) 1+0+1+0+0 = 2; 2/87 = 2.30% (exact 95% CI 0.3% to 8.1%)
TRSAE ("treatment-related severe adverse events"), total Table 3 2 (2.3%) 1+0+1+0+0 = 2; 2/87 = 2.3%
≥ Grade 3 TRAE, HNSCC Table 3; Results (grade 5 dyspnea) 1 (3.6%) 1/28 = 3.57% (exact 95% CI 0.1% to 18.3%)
≥ Grade 3 TRAE, sarcoma Table 3; Results (grade 3 anemia) 1 (2.3%) 1/44 = 2.27% (exact 95% CI 0.1% to 12.0%)
Grade ≥ 3 TRAEs if the dyspnea were judged unrelated — — 1/87 = 1.15% (exact 95% CI 0.03% to 6.2%): still not zero
TEAE leading to death Table 3; Results > Safety 6 (6.9%), "none of these was attributed to T3011" 3+1+1+0+1 = 6; 6/87 = 6.9%; listed causes 1+1+1+1+2 = 6, one of them dyspnea
Grade 5 TRAE Results > Safety 1 (dyspnea, HNSCC) conflicts with 0 deaths attributed to T3011 in the same paragraph
Any-grade TEAE Table 3; Results 77 (88.5%) 24+8+42+1+2 = 77; 77/87 = 88.5%
≥ Grade 3 TEAE Table 3; Results 15 (17.2%) 4+2+8+0+1 = 15; 15/87 = 17.2%
Any-grade TRAE Table 3; Results 55 (63.2%) 12+7+33+1+2 = 55; 55/87 = 63.2%
SAE Table 3 13 (14.9%) 3+1+8+0+1 = 13; 13/87 = 14.9%
TRAEs ≥ 5% (7 terms) Table 4; Results 9, 9, 6, 6, 5, 5, 5 of 87 all row sums and percentages match

For reference, an observed count of 0 of 87 would carry an exact 95% upper bound of 4.2%; the reported count of 2 gives an interval reaching 8.1%.

Figure

The Abstract and Discussion state zero severe or serious TRAEs; the Results and Table 3 count two, one of them graded fatal

Figure 1. The two summary statements (orange panel: Abstract, Results and Discussion) and the paper's own detailed safety reporting for Part III (blue panel: Results > Safety and Table 3), with the cohort counts of the two relevant Table 3 rows summed by recompute.py.txt. Conflict 1: the summary statements say zero severe or serious TRAEs, while the detail gives 2 of 87 patients (2.3%; exact 95% CI 0.3% to 8.1%), under both "≥ Grade 3 TRAE" and "TRSAE", which the Table 3 footer defines as treatment-related severe adverse events. Conflict 2 (gray panel): the same Results paragraph calls one of the two a grade 5 dyspnea TRAE, which under CTCAE v5.0 means death related to the adverse event, but then says none of the 6 deaths, one of whose listed causes is dyspnea, "was attributed to T3011". All text in the figure is quoted or summarized from the paper; no figure or image from the paper is reproduced.

Why it matters

Explanations considered

Status

Suggested correction

  1. Replace the Abstract sentence "No dose-limiting toxicities (DLTs) or severe treatment-related adverse events (TRAEs) were reported." with a statement that matches the Results, for example: "No DLTs occurred in Parts I and II. In Part III, grade ≥ 3 TRAEs occurred in 2 of 87 patients (2.3%): one grade 5 dyspnea (HNSCC) and one grade 3 anemia (sarcoma)."
  2. Revise the Discussion sentence "No DLTs or serious TRAEs were observed" in the same way, and reconsider the "favorable safety profile … particularly in patients with recurrent or metastatic HNSCC" wording in the Conclusions in light of the grade 5 TRAE in that cohort.
  3. Resolve the attribution of the fatal dyspnea. Either it was treatment-related, in which case "none of these was attributed to T3011" should be corrected, or it was not, in which case Table 3 (≥ Grade 3 TRAE and TRSAE) and the Results sentence should be corrected to 1 (1.1%). In either case the remaining grade 3 anemia means the Abstract cannot say that no severe TRAEs occurred.
  4. State whether DLT assessment applied to Part III and, if it did, whether the grade 5 event occurred within the 28-day DLT window.
  5. Minor: correct the Table 3 row label "≥ Grade TEAE" to "≥ Grade 3 TEAE", and add the missing percentage (2.3) to the sarcoma cell of "TEAE leading to death".